New press release out: HCS Pharma participates in the development of an improved biomimetic liver model on chip for drug discovery

HCS Pharma announces the closure of the “MIMLIVERonChip” project, funded by the French National Research Agency (ANR, project ANR 19 CE19-0020) and coordinated by BMBI Biomechanics and Bioengineering joint research unit (UTC/ CNRS), headed by Dr Cécile Legallais, CNRS research director. This project led to the publication of Taha Messelmani’s Read more…

Feedback of Rania’s internship about the development of primary human hepatocyte model in biochip microfludic system

This is the end of Rania‘s 6-month internship in HCS Pharma about a new liver biochip system. After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular Read more…

New press release out: HCS Pharma, LumiSTAR Biotech & MolDev explore stem cell-derived organoids for drug screening

In Asia for a business trip, Nathalie Maubon, PhD, CEO & CSO of HCS Pharma, participated in a symposium during BioAsia event on late July, together with LumiSTAR Biotechnology (Taïwan) and Molecular Devices (USA). On this occasion, the 3 companies have highlighted their work on hiPSCs (human induced Pluripotent Stem Read more…

HCS Pharma is delighted to help Vidac Pharma in the fight against cancer

Rehovot (Israel) London (UK) and Lille (France) Vidac Pharma is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. Vidac Pharma and HCS Pharma announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma Read more…

HCS Pharma will be present at next ELRIG event “Research and Innovation 2023 – Accelerating future DD” in Cambridge on March 29 and 30th

We are pleased to participate in ELRIG event about Research an Innovation 2023 – Accelerating future drug discovery” in Cambridge on March 29 and 30th 2023. Veronique De Conto, our project leader in in vitro Pharmacology, is very happy to meet with you and to present you our disruptive technology Read more…

Presentation of BIOMIMESYS technology, the first organ-specific in vitro ECM, to develop innovative and predictive 3D cellular models for drug discovery – Academia Sinica, the 1st of November 2022

BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…